DK2928870T3 - Neurotensin-receptorligander - Google Patents
Neurotensin-receptorligander Download PDFInfo
- Publication number
- DK2928870T3 DK2928870T3 DK13814827.5T DK13814827T DK2928870T3 DK 2928870 T3 DK2928870 T3 DK 2928870T3 DK 13814827 T DK13814827 T DK 13814827T DK 2928870 T3 DK2928870 T3 DK 2928870T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor ligands
- neurotensin receptor
- neurotensin
- ligands
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12008208.6A EP2740726A1 (en) | 2012-12-07 | 2012-12-07 | Neurotensin receptor ligands |
| PCT/EP2013/003700 WO2014086499A1 (en) | 2012-12-07 | 2013-12-06 | Neurotensin receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2928870T3 true DK2928870T3 (da) | 2020-07-13 |
Family
ID=47355771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20166422.4T DK3712131T3 (da) | 2012-12-07 | 2013-12-06 | Neurotensinreceptorligander |
| DK13814827.5T DK2928870T3 (da) | 2012-12-07 | 2013-12-06 | Neurotensin-receptorligander |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20166422.4T DK3712131T3 (da) | 2012-12-07 | 2013-12-06 | Neurotensinreceptorligander |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10961199B2 (da) |
| EP (3) | EP2740726A1 (da) |
| JP (2) | JP6576828B2 (da) |
| KR (1) | KR102290803B1 (da) |
| CN (2) | CN109320502B (da) |
| AU (1) | AU2013354422B2 (da) |
| BR (1) | BR112015012530B1 (da) |
| CA (1) | CA2893605C (da) |
| DK (2) | DK3712131T3 (da) |
| ES (2) | ES2795923T3 (da) |
| FI (1) | FI3712131T3 (da) |
| HK (1) | HK1210148A1 (da) |
| HU (2) | HUE050388T2 (da) |
| IL (1) | IL239080B (da) |
| MX (1) | MX370354B (da) |
| PL (2) | PL3712131T3 (da) |
| PT (2) | PT3712131T (da) |
| RU (1) | RU2671970C2 (da) |
| SG (2) | SG10201704564QA (da) |
| WO (1) | WO2014086499A1 (da) |
| ZA (1) | ZA201503446B (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2954933A1 (en) * | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand |
| EP2954934A1 (en) * | 2014-06-11 | 2015-12-16 | 3B Pharmaceuticals GmbH | Conjugate comprising a neurotensin receptor ligand and use thereof |
| CA2949936C (en) | 2014-06-10 | 2022-10-18 | 3B Pharmaceuticals Gmbh | Conjugate comprising a neurotensin receptor ligand and use thereof |
| DK3380495T3 (da) * | 2015-11-24 | 2021-08-16 | Transfert Plus Sec | Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi |
| EP3279197A1 (en) | 2016-08-03 | 2018-02-07 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnosis, treatment and prevention of neurotensin receptor-related conditions |
| MX2019006448A (es) | 2016-12-01 | 2020-02-05 | Regeneron Pharma | Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet. |
| EP3580238A1 (en) | 2017-02-10 | 2019-12-18 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| MX2020000916A (es) | 2017-07-24 | 2020-09-10 | Regeneron Pharma | Anticuerpos anti-cd8 y usos de estos. |
| US20220273831A1 (en) * | 2019-07-08 | 2022-09-01 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| CN111875667B (zh) * | 2020-07-16 | 2021-12-21 | 南方科技大学 | 有机金属螯合物及其制备方法与应用、探针 |
| IL301868A (en) * | 2020-10-22 | 2023-06-01 | Nihon Mediphysics Co Ltd | Method for producing radioactive zirconium complex |
| AU2022273867A1 (en) * | 2021-05-13 | 2023-11-23 | The General Hospital Corporation | Molecular probes for in vivo detection of aldehydes |
| EP4355377A1 (en) * | 2021-06-16 | 2024-04-24 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel |
| EP4355325A1 (en) * | 2021-06-16 | 2024-04-24 | Fusion Pharmaceuticals Inc. | Combination comprising a neurotensin receptor binding compound and folfirinox |
| MX2024009317A (es) * | 2022-01-28 | 2024-08-06 | Fusion Pharmaceuticals Inc | Radiofarmacos dirigidos a ntsr1 y terapia de combinacion de inhibidores punto de control. |
| AU2023221977A1 (en) | 2022-02-18 | 2024-08-15 | Full-Life Technologies Hk Limited | Compounds and radioligands for targeting neurotensin receptor and uses thereof |
| EP4518912A1 (en) * | 2022-05-03 | 2025-03-12 | The University of North Carolina at Chapel Hill | Development of ntsr targeted agents for imaging and therapy applications |
| US12091454B2 (en) | 2022-12-28 | 2024-09-17 | Development Center For Biotechnology | Humanized anti-human neurotensin receptor 1 antibodies and their uses |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110321A (en) | 1976-07-12 | 1978-08-29 | Folkers Karl | Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity |
| US4425269A (en) | 1982-06-07 | 1984-01-10 | Merck & Co., Inc. | Metabolically protected analogs of neurotensin |
| US4439359A (en) | 1982-07-02 | 1984-03-27 | Merck & Co., Inc. | Cyclic octapeptide analogs of neurotensin |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| US5021556A (en) | 1987-07-22 | 1991-06-04 | Neorx Corporation | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides |
| US5075099A (en) | 1988-05-31 | 1991-12-24 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5364613A (en) | 1989-04-07 | 1994-11-15 | Sieving Paul F | Polychelants containing macrocyclic chelant moieties |
| FR2665898B1 (fr) | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5367080A (en) | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
| US5965107A (en) | 1992-03-13 | 1999-10-12 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| CA2086453A1 (en) | 1992-12-30 | 1994-07-01 | Mcgill University | Marker for neurotensin receptor |
| US5407916A (en) | 1993-02-16 | 1995-04-18 | Warner-Lambert Company | Neurotensin mimetics as central nervous system agents |
| FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
| WO1995022341A1 (en) | 1994-02-18 | 1995-08-24 | Mallinckrodt Medical, Inc. | Labelled peptide compounds |
| US6054557A (en) | 1995-04-04 | 2000-04-25 | Advanced Bioconcept (1994) Ltd. | Fluorescent peptides |
| EP0820466A2 (en) | 1995-04-04 | 1998-01-28 | Advanced Bioconcept Inc. | Fluorescent peptides |
| FR2732967B1 (fr) * | 1995-04-11 | 1997-07-04 | Sanofi Sa | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant |
| AU6352296A (en) | 1995-07-20 | 1997-02-18 | Advanced Bioconcept, Inc. | Cell sorting with fluorescent peptides |
| DE69819478T2 (de) | 1997-02-03 | 2004-09-02 | Mallinckrodt, Inc. | Verfahren zum Nachweis und zur Lokalisierung maligner menschlicher Pankreastumore |
| US5886142A (en) | 1997-05-20 | 1999-03-23 | Thomas Jefferson University | Radiolabeled thrombus imaging agents |
| WO1999052539A1 (en) | 1998-04-10 | 1999-10-21 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| WO2000078796A2 (en) | 1999-06-24 | 2000-12-28 | Mallinckrodt Inc. | Labeled neurotensin derivatives with improved resistance to enzymatic degradation |
| CA2530224A1 (en) * | 2003-07-09 | 2005-02-24 | California Pacific Medical Center | Remote detection of substance delivery to cells |
| US20060062729A1 (en) * | 2004-09-09 | 2006-03-23 | Carraway Robert E | Enhanced ligand binding to neurotensin receptors |
| JP2010516679A (ja) * | 2007-01-19 | 2010-05-20 | マリンクロット インコーポレイテッド | 診断用および治療用シクロオキシゲナーゼ−２結合リガンド |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| US8487077B2 (en) * | 2008-09-16 | 2013-07-16 | The Regents Of The University Of California | Simplified one-pot synthesis of [18F]SFB for radiolabeling |
| MX2011005963A (es) | 2008-12-05 | 2011-09-01 | Angiochem Inc | Conjugados de neurotensina o analogos de neurotensina y sus usos. |
| EP2374003B1 (en) * | 2009-01-07 | 2015-03-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment, the prognostic assessment and the detection of breast cancer |
| US9809624B2 (en) | 2009-07-16 | 2017-11-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors |
| WO2011156557A2 (en) * | 2010-06-11 | 2011-12-15 | Thomas James B | Compounds active at the neurotensin receptor |
-
2012
- 2012-12-07 EP EP12008208.6A patent/EP2740726A1/en not_active Withdrawn
-
2013
- 2013-12-06 CN CN201811305966.0A patent/CN109320502B/zh active Active
- 2013-12-06 CN CN201380063364.8A patent/CN104837819B9/zh active Active
- 2013-12-06 AU AU2013354422A patent/AU2013354422B2/en active Active
- 2013-12-06 US US14/650,437 patent/US10961199B2/en active Active
- 2013-12-06 DK DK20166422.4T patent/DK3712131T3/da active
- 2013-12-06 HU HUE13814827A patent/HUE050388T2/hu unknown
- 2013-12-06 SG SG10201704564QA patent/SG10201704564QA/en unknown
- 2013-12-06 KR KR1020157018171A patent/KR102290803B1/ko active Active
- 2013-12-06 MX MX2015007193A patent/MX370354B/es active IP Right Grant
- 2013-12-06 ES ES13814827T patent/ES2795923T3/es active Active
- 2013-12-06 RU RU2015127086A patent/RU2671970C2/ru active
- 2013-12-06 EP EP13814827.5A patent/EP2928870B1/en active Active
- 2013-12-06 PT PT201664224T patent/PT3712131T/pt unknown
- 2013-12-06 WO PCT/EP2013/003700 patent/WO2014086499A1/en active Application Filing
- 2013-12-06 PL PL20166422.4T patent/PL3712131T3/pl unknown
- 2013-12-06 CA CA2893605A patent/CA2893605C/en active Active
- 2013-12-06 FI FIEP20166422.4T patent/FI3712131T3/fi active
- 2013-12-06 ES ES20166422T patent/ES2941629T3/es active Active
- 2013-12-06 SG SG11201503880YA patent/SG11201503880YA/en unknown
- 2013-12-06 BR BR112015012530-1A patent/BR112015012530B1/pt active IP Right Grant
- 2013-12-06 JP JP2015545697A patent/JP6576828B2/ja active Active
- 2013-12-06 DK DK13814827.5T patent/DK2928870T3/da active
- 2013-12-06 HU HUE20166422A patent/HUE061839T2/hu unknown
- 2013-12-06 EP EP20166422.4A patent/EP3712131B1/en active Active
- 2013-12-06 PL PL13814827T patent/PL2928870T3/pl unknown
- 2013-12-06 PT PT138148275T patent/PT2928870T/pt unknown
-
2015
- 2015-05-18 ZA ZA2015/03446A patent/ZA201503446B/en unknown
- 2015-05-28 IL IL239080A patent/IL239080B/en active IP Right Grant
- 2015-11-03 HK HK15110838.8A patent/HK1210148A1/xx unknown
-
2019
- 2019-08-21 JP JP2019150947A patent/JP7042776B2/ja active Active
-
2020
- 2020-12-04 US US17/112,258 patent/US20210087149A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3712131T3 (da) | Neurotensinreceptorligander | |
| DK2825087T3 (da) | Otoscanner | |
| EP2809145A4 (en) | CHLOROPLAST TRANSIT PEPTIDES | |
| DK2839013T3 (da) | Ikke-disruptiv-gen-targetering | |
| EP2814472A4 (en) | DITHIOAMINE REDUCING AGENTS | |
| EP2805877A4 (en) | UNDER HOOD | |
| DK2873977T3 (da) | Dobbeltdækker-rørdispenser | |
| DE112012006109A5 (de) | Okklusionsschienenanordnung | |
| FR2998638B1 (fr) | Raccord | |
| DK2825157T3 (da) | Aminosyrelipider | |
| EP2812047A4 (en) | ACCESS SYSTEM VIA AN OCCLUSION | |
| DK2831122T3 (da) | Anthocyanidin-kompleks | |
| EP2801315A4 (en) | SCANNING ENDOSCOPE DEVICE | |
| DE112012005566T8 (de) | Seltenerdnanoverbundmagnet | |
| DK2885638T3 (da) | Molekylenet | |
| DE102013212400A8 (de) | Abdeckplattenstützbaugruppe | |
| DK2897570T3 (da) | Spin-elueringsrør | |
| DE202012013401U8 (de) | Bioextruder | |
| DE102012100780A8 (de) | Zugmittelhebevorrichtung | |
| DK2931704T3 (da) | Thiolfunktionel forbindelse | |
| FR2999675B1 (fr) | Electro-clapet ameliore | |
| BR302012006128S1 (pt) | Configuracao aplicada em chinelo | |
| BR302012006127S1 (pt) | Configuracao aplicada em chinelo | |
| BR302012006126S1 (pt) | Configuracao aplicada em chinelo | |
| BR302012006124S1 (pt) | Configuracao aplicada em chinelo |